The LIDS demo achieved its Main endpoint with statistical importance for your 150mg BID dose. Linsitinib With this trial validated the protection profile seen inside the prior oncology experiments and importantly shown a positive safety profile on crucial adverse gatherings (AEs) of desire for the I